---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Natural history, survival, and mortality"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Natural history, survival, and mortality. Topics: U.S. breast cancer deaths, 2026; U.S. death rate and age at death; Contribution of metastatic disease treatment to the decline in U.S. mortality; U.S. 5-year relative survival by stage at diagnosis, SEER 21, 2016 to 2022; 13 further topics. 17 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### U.S. breast cancer deaths, 2026

> “An estimated 42,670 breast cancer deaths (42,140 in women, 530 in men) will occur in 2026.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

> “Breast cancer is the second leading cause of cancer death in women, after lung cancer.”
> “Breast cancer death rates have been decreasing steadily since 1989, for an overall decline of 44% through 2023.”

Source: [American Cancer Society Key Statistics for Breast Cancer (2026)](https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html)

<a id="topic-2.2.1.3-2"></a>

### U.S. death rate and age at death

> “The death rate was 18.9 per 100,000 women per year based on 2020–2024, age-adjusted.”
> “The percent of female breast cancer deaths is highest among women aged 65–74.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.3-3"></a>

### Contribution of metastatic disease treatment to the decline in U.S. mortality

> “A recent modeling study estimated that most of the reduction in mortality is attributable to advances in the treatment of stage I–III disease (47%) and metastatic disease (29%), with an additional 25% associated with earlier detection through screening.”

Source: [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)

<a id="topic-2.2.1.3-4"></a>

### U.S. 5-year relative survival by stage at diagnosis, SEER 21, 2016 to 2022

| Stage at diagnosis | 5-year relative survival |
| --- | --- |
| Localized | “100.0%” |
| Regional | “87.5%” |
| Distant | “33.8%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.3-5"></a>

### U.S. 5-year relative survival for HR-positive/HER2-negative disease by stage, SEER 21, 2016 to 2022

| Subtype | Localized | Regional | Distant |
| --- | --- | --- | --- |
| HR+/HER2- | “100.0%” | “91.1%” | “38.1%” |
| HR-/HER2- | “92.8%” | “68.3%” | “14.9%” |
| HR+/HER2+ | “99.5%” | “91.5%” | “48.7%” |
| HR-/HER2+ | “97.8%” | “86.4%” | “43.1%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

> “While breast cancer subtype affects survival, stage at diagnosis may be the most powerful factor in determining survival outcome.”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.3-6"></a>

### Goals of treatment for metastatic disease

> “Treatment of metastatic disease is palliative in intent. Goals of treatment include prolonging life and improving quality of life.”
> “The longest median survival outcomes have been observed in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor–positive metastatic breast cancer, and less favorable outcomes have been observed in patients with metastatic triple-negative breast cancer (TNBC).”

Source: [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)

<a id="topic-2.2.1.3-7"></a>

### U.S. survival after de novo metastatic diagnosis over time

> “Median relative survival time increased from 22.3 to 38.7 months and from 19.1 to 29.7 months for women diagnosed between ages 15–49 and 50–64, respectively, during 1992–1994 versus 2005–2012.”
> “Despite a poor prognosis there is a small but meaningful percent of these cases who survive 10-years or more; more than 11% of women diagnosed between 2000–2004 under the age of 64 years survived 10 years or more.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.3-8"></a>

### U.S. breast cancer-specific survival in de novo HR-positive/HER2-negative metastatic disease before and after CDK4/6 inhibitors

> “In the unadjusted analysis of patients with HR+/HER2− mBC, BCSS was significantly longer among patients in the post-2015 group versus the pre-2015 group (median BCSS: 39 [95% CI 38–42] vs 35 [95% CI 33–37] months; hazard ratio [HR] = 0.896, 95% CI 0.849–0.946; p < 0.001;”
> “The 48-month BCSS rate was 44.5% for the post-2015 group and 38.5% for the pre-2015 group”

Source: [Brufsky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11455714/)

<a id="topic-2.2.1.3-9"></a>

### U.S. real-world overall survival with first-line CDK4/6 inhibitor plus aromatase inhibitor

> “Of 9146 eligible patients, 6831, 1279, and 1036 received palbociclib plus AI, ribociclib plus AI, or abemaciclib plus AI, respectively.”
> “After sIPTW, median OS was 54.6 months (95% CI 52.6-56.4 months) in the palbociclib group, 59.0 months (95% CI 50.9-66.1 months) in the ribociclib group, and 64.5 months (95% CI 55.4 months-not estimable) in the abemaciclib group.”

Source: [Rugo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11758200/)

<a id="topic-2.2.1.3-10"></a>

### U.S. real-world outcomes of second-line therapy after progression on a first-line CDK4/6 inhibitor

> “A total of 839 patients received a documented second-line therapy after progression on first-line CDK4/6i treatment.”
> “The median unadjusted rwPFS and OS for those who received a CDK4/6i in the second-line setting were 8.25 months and 35.7 months, respectively”
> “The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.1.3-11"></a>

### Systematic review: real-world progression-free survival after a first-line CDK4/6 inhibitor

> “Twenty records (9 full-text articles and 11 conference abstracts) encompassing 18 unique studies met the eligibility criteria and reported outcomes for second-line (2 L) treatments after 1 L CDK4/6i; no studies reported disaggregated outcomes in the third-line setting or beyond.”
> “The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.1.3-12"></a>

### Second- and third-line real-world progression-free survival by intrinsic subtype, Spain

> “Median rwPFS-2L was 7.2 months in luminal IS vs. 6.1 in non-luminal (HR 1.40; 95% CI 0.86–2.30); the Basal-like (BL) subtype correlated with significantly shorter rwPFS-2L (HR 3.82; 95% CI 1.07–13.63).”
> “In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="topic-2.2.1.3-13"></a>

### Acquired ESR1 mutations along the treatment course

> “Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease”
> “Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.”
> “In addition, ESR1 mutations usually occur with several concurrent genomic alterations, and together, these confer a globally worse prognosis”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

> “ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).”
> “Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.3-14"></a>

### ESR1 mutation and overall survival after prior aromatase inhibitor, BOLERO-2

> “Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.”
> “These mutations were associated with shorter overall survival (wild-type, 32.1 months [95% CI, 28.09-36.40 months]; D538G, 25.99 months [95% CI, 19.19-32.36 months]; Y537S, 19.98 months [13.01-29.31 months]; both mutations, 15.15 months [95% CI, 10.87-27.43 months]).”

Source: [Chandarlapaty et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5063698/)

<a id="topic-2.2.1.3-15"></a>

### Worldwide population-level survival trends in de novo and recurrent metastatic disease

> “For dnMBC, 13 of 14 studies reported improved OS or BCSS since 1995. In 2005–2009, the median OS was 26 months (range 24–30), a median gain of 6 months since 1995–1999 (range 0–9, 4 studies).”
> “For rMBC, one study reported no change in survival between 1998 and 2006 and 2007–2013 (median OS 23 months).”
> “Population-level improvements in OS for dnMBC have not been consistently observed in rMBC cohorts nor older women.”

Source: [Lord et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8804182/)

<a id="topic-2.2.1.3-16"></a>

### Worldwide mortality, GLOBOCAN 2024

> “Among women, breast cancer is the most common cancer for both incidence and mortality worldwide, ranking first for incidence in 164 countries”
> “Mortality rates range from 20 to 25 per 100,000 in Melanesia, Micronesia/Polynesia, and Western Africa and from six to 10 per 100,000 in Eastern Asia and Central America.”

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.3-17"></a>

### Worldwide survival gains in ER-positive/HER2-negative advanced disease

> “While important progress has been made, including the doubling of the median overall survival for two of the three ABC subtypes, the disease remains incurable for the vast majority of patients and inequities in access to the best diagnostic and therapeutic options and to high quality, multidisciplinary, evidence-based care have increased in the last decade.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

Additional sources: [Howlader et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29593010/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
